NPNT (Gene)

Synonyms:EGFL6L, ENTREZ:255743, HGNC:27405, MIM:610306, NM_001033047, NM_001184690, NM_001184691, NM_001184692, NM_001184693, NM_198278, NPNT, NP_001028219, NP_001171619, NP_001171620, NP_001171621, NP_001171622, POEM, XM_005262888, XM_011531820, XM_011531822, XM_011531823, XM_011531824, XM_011531825, XM_017007984, XP_005262945, XP_011530122, XP_011530124, XP_011530125, XP_011530126, XP_011530127, XP_016863473, nephronectin
Id:ENSG00000168743
Entrez:255743
Description:nephronectin
Predicted to enable integrin binding activity. Predicted to be involved in several processes, including cell-cell adhesion mediated by integrin; positive regulation of ERK1 and ERK2 cascade; and positive regulation of osteoblast differentiation. Predicted to act upstream of or within positive regulation of transforming growth factor beta receptor signaling pathway. Located in extracellular exosome. Part of collagen-containing extracellular matrix. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View NPNT's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with NPNT.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using NPNT.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for NPNT.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with NPNT.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.